ACCELERATING DISCOVERY AND DEVELOPMENT OF NEW PRODUCTS ADDRESSING UNMET CLINICAL NEED.
VIC explores and develops new ways to modulate the immune system for therapeutic benefit in the context of cancer, infectious and immune mediated disease including Type 1 Diabetes and ALS.
Our approach is deeply collaborative and involves leveraging the expertise and direct involvement of academic and industry scientists from US and abroad.
We currently have nine products in our pipeline including a novel biologic immunotherapy for specific forms of cancer, a vaccine for HPV related cancer, a novel microencapsulant to enable allogeneic cell or tissue transplantation without systemic immune suppression and a novel immune cell based therapy for ALS and traumatic brain injury.
VIC supports rapid-pace, high-impact research initiatives that are in the process of safely transitioning from the research lab to patients
Accelerating innovation relies on two things; the disciplined focus on the VIC mission and the generosity of donors who share our goals. Development of our new vaccines and immunotherapies can only be achieved with additional support beyond grants and contracts. We are very grateful to our donors for their visionary support of our scientists and the work at VIC.